Cargando…
Glycogen Reduction in Myotubes of Late-Onset Pompe Disease Patients Using Antisense Technology
Glycogen storage disease type II (GSDII) is a lysosomal disorder caused by the deficient activity of acid alpha-glucosidase (GAA) enzyme, leading to the accumulation of glycogen within the lysosomes. The disease has been classified in infantile and late-onset forms. Most late-onset patients share a...
Autores principales: | Goina, Elisa, Peruzzo, Paolo, Bembi, Bruno, Dardis, Andrea, Buratti, Emanuele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589062/ https://www.ncbi.nlm.nih.gov/pubmed/28629821 http://dx.doi.org/10.1016/j.ymthe.2017.05.019 |
Ejemplares similares
-
Deferoxamine mesylate improves splicing and GAA activity of the common c.-32-13T>G allele in late-onset PD patient fibroblasts
por: Buratti, Emanuele, et al.
Publicado: (2020) -
Distribution of Exonic Variants in Glycogen Synthesis and Catabolism Genes in Late Onset Pompe Disease (LOPD)
por: De Filippi, Paola, et al.
Publicado: (2023) -
Exercise training alone or in combination with high-protein diet in patients with late onset Pompe disease: results of a cross over study
por: Sechi, Annalisa, et al.
Publicado: (2020) -
Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease
por: Clayton, Nicholas P, et al.
Publicado: (2014) -
Respiratory muscle training with enzyme replacement therapy improves muscle strength in late - onset Pompe disease
por: Mitja, Jevnikar, et al.
Publicado: (2015)